Skip to main content

Table 6 Main patient outcomes according to previous major cardiovascular event

From: Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Group No previous cardiovascular event Previous cardiovascular event
Generic Brand-name p Generic Brand-name p
Number of patients, % N = 8292 (77.1%) N = 2457 (22.9%) N = 1280 (78.0%) N = 550 (22.0%)
Sociodemographics
 Age, mean (SD), years 59.9 (11.3) 60.1 (11.6) 0.427 67.0 (9.6) 67.2 (10.3) 0.640
 Sex (female) 54.5% 54.9% 0.681 44.1% 42.9% 0.630
Comorbidity
 Number of comorbidities 6.3 (3.2) 6.4 (3.5) 0.198 7.5 (3.4) 7.8 (4) 0.087
 Charlson index 0.6 (1.0) 0.6 (0.9) 0.675 1.2 (1.0) 1.3 (1.1) 0.935
 RUB 2.9 (0.7) 2.9 (0.7) 0.485 3.3 (0.8) 3.3 (0.8) 0.755
Adherence
 Medication possession ratio (%) 59.4% 62.6% p = 0.015 71.0% 76.0% p = 0.002
Treatment persistence (%, HR)* 17.0% 22.8% 0.86 [0.82–0.91]; p < 0.001 36.1% 42.0% 0.88 [0.78–0.99]; p = 0.034
Patients who have reached LDL-c goal (%)**
 At the start of statin therapy 18.5 [17.7–19.3] 18.8 [17.3–20.3] 0.710 14.1 [12.2–16.0] 13.6 [10.8–16.5] 0.764
 At discontinuation 37.2 [36.2–38.2] 39.4 [37.5–41.3] OR; 0.89 [0.80–0.99]; p = 0.025 48.0 [45.2–50.7] 53.5 [49.3–57.6] OR; 0.78 [0.64–0.95]; p = 0.015
 Absolute variation 18.7 20.6 0.035 33.8 39.8 0.014
Patient Outcomes (IR)***
 - Cardiovascular event 29.08 [26.82–31.50] 24.69 [21.06–28.77] 0.062 74.42 [67.89–81.42] 55.41 [45.41–66.96] 0.006
 - All-cause mortality 20.51 [18.61–22.55] 16.86 [13.88–20.29] 0.064 39.71 [34.98–44.91] 26.41 [19.67–34.73] 0.007
Costs (€)**** Generic Brand-name Difference Generic Brand-name Difference
Healthcare costs 8365 [8285–8445] 7751 [7584–7918] 614 [432–796]; p < 0.001 12,081 [11890–12,271] 10,421 [10078–10,763] 1660 [1280–2040]; p < 0.001
Productivity losses 1101 [1047–1156] 981 [873–1089] 120 [12–232]; p = 0.068 15,337 [14443–16,230] 14,890 [13007–16,773] 447 [117–777]; p = 0.683
Total costs 9466 [9368–9565] 8732 [8536–8928] 734 [516–952]; p = 0.001 27,417 [26523–28,311] 25,310 [23512–27,110] 2107 [1805–2409]; p < 0.001
  1. Values expressed as mean with standard deviation or 95% confidence interval (CI) in brackets; IR: unadjusted cumulative incidence rate in number of cases per 1000 person-years, *HR: adjusted hazard ratio relative to brand-name statin (adjusted using a Cox proportional risk model with covariates (age, sex, number of comorbidities, Charlson index, resource utilization band [RUB], proportion of subjects reaching their LDL-cholesterol (LDL-c) goal at start of therapy, statin type and prior cardiovascular event); **OR: Odds ratio, adjusted by age, sex, number of comorbidities, Charlson index, RUB, proportion of subjects reaching their LDL-c goal at the start of therapy and statin type; ***p values using the Mantel-Haenszel Chi-square test.****Adjusted by age, sex, number of comorbidities, Charlson index, RUB, proportion of subjects reaching their LDL-c goal at the start of therapy, statin type, prior cardiovascular event and treatment duration. 95% CI calculated with 1000 non-parametric bootstrap iterations